# OPPENHEIMER MEDTECH, TOOLS & DIAGNOSTICS SUMMIT

May 26, 2021

Anthony Fernando, President & CEO

Shameze Rampertab, EVP & CFO

# Forward Looking Statements

This presentation includes statements relating to our vision for the future of performance-guided surgery and the role the Senhance® Surgical System may play. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, and include whether we will be well-positioned to continue to deliver on our strategy and bring transformative technology to surgeons, hospitals and patients globally. For a discussion of the risks and uncertainties associated with our business, please review our filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the date this presentation was first made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.



We believe in digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking the Clinical Intelligence to enable consistently superior outcomes and a new standard of surgery.

# Asensus Surgical (NYSE American:ASXC)

Early-Commercial Stage Company Ushering In A New Era Of Minimally Invasive Surgery

Global Regulatory Approvals

Global Training Centers

**100+** Active Surgeon Users

Active Clinical Sites in US, EU & Asia

**4,500+** Surgeries Performed

Compelling Per Procedure Economics

**1st**

eye-sensing camera control
haptic feedback
3 mm robotic instruments
augmented intelligence and machine vision
real-time surgical image analytics
pediatrics with robotic 3 mm

Strong Talented Global Team

Integrated Remote Mentoring

ASENSUS SURGICAL

# Global Market Trends in Surgical Robotics




SURGICAL ROBOTICS IS A LARGE AND FAST-GROWING MARKET AND CONVERTING LAPAROSCOPIC SURGERY IS A GREENFIELD OPPORTUNITY

## Worldwide Robotic Penetration Rate is < 5%, Today




Sources: Goldman Sachs Global Investment Research, Healthcare Cost and Utilization Project (HCUP), Global Market Insights, Mordor Intelligence, company analysis

# We Are Uniquely Focused on Laparoscopy

## An Opportunity And Need To Add To The Ways Surgical Robotics Creates Value

### Global Soft Tissue Abdominal Surgery Market

| | Laparoscopy: ~16 million | | Open: ~37 million |
|---|---|---|---|
| Applicable Technology | Digital Laparoscopy (multi-port) | | Robotic Assisted Surgery (multi-port) |
| Industry Participants | ASENSUS SURGICAL | | INTUITIVE SURGICAL, Medtronic, J&J, CMR SURGICAL |
| Surgical Technique | Laparoscopy | | Open Surgery / Hybrid MIS |
| Instruments | Fully Reusable | • Low $ / procedure | Limited / Single Use |
| | 5mm & 3mm | • Advances MIS, broadens applicability | 8mm & 5mm |
| | Articulating | • Enabling where needed | Wristed |
| Advanced Technology | Intelligent Capabilities | • Evolving capabilities of surgeons | Not Available |

***Senhance is the only platform able to address the conversion of laparoscopy by leveraging standard laparoscopic tools, digital information and decision support tools***

***Competitors are following the Da Vinci model and focusing on open surgery conversion***

ASENSUS SURGICAL

# Senhance System Addresses Key Challenges Facing Hospitals and Laparoscopic Surgeons

## Building The Bridge From Laparoscopy To Robotics

Senhance®

**Standard reusable instruments** keep costs similar to traditional laparoscopic instruments

**Digital laparoscopy** maintains familiar motion, ancillary tools, and techniques

A **digital fulcrum** sets a dynamic virtual pivot point that helps potentially minimize the incision trauma

The **3DHD visualization** provides the surgeon with additional intelligence regarding depth and spatial relation of organs

**Eye-tracking camera control** where the system can sense the surgeon's eye activity, allowing camera control

**Open-platform architecture** allows use and integration of existing OR technologies to maximize benefit from capital investments and support surgeon preference

**Haptic sensing** of the platform heightens the surgeon sensing of pressure/ tension through alerts if pressure threshold is reached for an added layer of security not currently available elsewhere

Allows the surgeon to be seated in an **ergonomically comfortable position** throughout the procedure

**Intelligent Surgical Unit™**
Brings AI and Machine Learning capabilities to surgery

**Senhance Connect**
On-Demand, 2-way communication enabling remote mentoring

ASENSUS SURGICAL

# Robust Global Applicability

## High Volume Procedural Approvals Widely Available To Address Significant Markets

| | United States<br>*FDA Approved* | | European Union<br>*CE Marked* | Japan<br>*PMDA Approved* | Rest of World<br>*Russia, Taiwan, Others* |
|---|---|---|---|---|---|
| **Senhance System Surgical** | ✓ | | ✓ | ✓ | ✓ |
| **Procedural Indications for Use** | | | | | |
| *General* | ✓ | *1Q-21 Clearance* | ✓ | ✓ | ✓ |
| *GYN* | ✓ | | ✓ | ✓ | ✓ |
| *Thoracic** | | | ✓ | | ✓ |
| *Pediatric* | | | ✓ | ✓ | |
| *Urology* | | | ✓ | ✓ | ✓ |

**Addressable Market**
*(# of annual procedures)*

**16 million**

*Non-cardiac, upper abdominal procedures

# Digitizing Laparoscopic Instrumentation

## Broad Instrumentation Add Unique Advantages For Surgeons And Patients

**Core Laparoscopic**


**Ultrasonic**

**3mm**

**Articulating**

*Filed for FDA Clearance 1Q21*

***Developed broad instrument portfolio with 70+ instruments in the catalog***

***New standard in minimally invasive robotic surgery with 3mm instruments***

***Reusable instruments enable compelling per procedure economics***

# Our Path To Market Leadership

Delivering A New Era In Digital Surgery

1. Educate surgeons on the benefits of Senhance
2. Grow global installed base
3. Increase global procedure volume
4. Expand the portfolio
5. Continue the technological advancement of Senhance

# 1 Educating Surgeons On The Benefits Of Senhance

## Grow Compelling Set of Data to Demonstrate Clinical and Economic Value

**60+**
**peer review articles to date**

Focused on the following data:

- Health economics
  - Cost per procedure
  - Procedure times/workflow
- Usability across specialties
- Clinical outcomes

The TransEnterix European Patient Registry for Robotic-Assisted Laparoscopic Procedures in Urology, Abdominal, Thoracic, and Gynecologic Surgery ("TRUST")

Dietmar Stephan [1,2], Ibra

Affiliations + expand

PMID: 33513657 DOI: 10.

Abstract

**Introduction:** Robotic surg
da Vinci® System (Intuitive
monopoly for years afterwa
Morrisville, North Carolina,
movements and is designe
patients after different visc
with the Senhance™ digita

**Materials and methods:** T
surgery with the Senhance
and bilateral), cholecystect
in Europe between Februa

First experience using the Senhance surgical system in laparoscopic local gastrectomy for gastrointestinal stromal tumor

Hirofumi Sugita [1], Shinichi Sakuramoto [1], Junya Aoyama [1], Sunao Ito [1], Shuichiro Oya [1], Kenji Watanabe [1], Naoto Fujiwara [1], Hiroka Kondo [1], Yutaka Miyawaki [1], Yasumitsu Hirano [1], Hiroshi Sato [1], Shigeki Yamaguchi [1], Isamu Koyama [1]

Affiliations + expand

PMID: 33590962 DOI: 10.111

Abstract

Various innovative robotic syst
Surgical System (SSS) is a digit
Several reports have described
and colectomy. However, use
case of laparoscopic local gast
74-year-old man diagnosed wi
times were 117, 11, and 59 mi
This study is the first to report
SSS can use reusable forceps a
instruments is also progressing

**Keywords:** GIST; Senhance su

© 2021 Japan Society for Endosco

Senhance surgical system in benign hysterectomy: A real-world comparative assessment of case times and instrument costs versus da Vinci robotics and laparoscopic-assisted vaginal hysterectomy procedures

Herbert Coussons [1], Josh Feldstein [1], Steve McCarus [2]

Affiliations + expand

PMID: 33860631 DOI: 10.1002/rcs.2261

Abstract

**Objectives:** Comparison of retrospective, learning curve benign hysterectomy cost and case time data from Senhance total laparoscopic hysterectomy (TLH) cases with similar da Vinci robot cases and laparoscopic-assisted vaginal hysterectomy (LAVH) cases.

**Methods:** Instrument costs, console time, and case time analysis from six surgeons at four U.S. and European hospitals compared with retrospective, sequential da Vinci TLH and standard laparoscopic LAVH cases extracted from the CAVAlytics database.

**Results:** Senhance Gyn surgeons in their learning curve when compared to da Vinci learning curve Gyn surgeons achieved lower median instrument costs ($559 vs. $1393, respectively, p < 0.001) with comparable console times (91.5 vs. 96 min, p = 0.898); Senhance and LAVH case costs were comparable ($559 vs. $498, p = 0.336).

## International Journal of Medical Robotics (Apr 2021)

*Senhance surgical system in benign hysterectomy: A real-world comparative assessment of case times and instrument costs versus da Vinci robotics and laparoscopic-assisted vaginal hysterectomy procedures*




- Senhance per procedure costs were less than half of da Vinci
- Senhance per procedure costs were in line with laparoscopy
- Case times between Senhance and da Vinci were comparable

# 2 Growing Global Installed Base

## Expanding Number of Systems Being Used Across Multiple Geographies



**28**
Active Installed Units

**6**
Global Training Centers

**13**
Foundational Sites

- 10 systems added in 2020
- 10 – 12 systems expected to be added in 2021
- 2 lease agreements signed YTD 2021

- 2 Training Centers added LTM (EU, Japan)

- Foundational Sites expected to expand in 2021

ASENSUS SURGICAL

# 3 Increasing Global Procedure Volumes

Senhance Demonstrating Strong Clinical Performance Across The Three Major Geographies

## GLOBAL CLINICAL CASE VOLUME TREND




| Year end Active Sites | 6 | 18 | 28 | 38-40** |
|---|---|---|---|---|

**Strong clinical case performance**

## 2020/2021* CASE MIX




**Adoption across multiple specialty areas, demonstrating broader applicability and adoption**

ASENSUS SURGICAL

* Close of 2021-Q1 **2021 estimates

# 4 Expanding The Portfolio

## Broadening Applicability Through Regulatory And Instrument Expansion

| | | |
|---|---|---|
| **1Q'21** | CE Marking: **Initial ISU™** | • Provided Senhance digital laparoscopy programs access to new Augmented Intelligence technology<br>• Brings initial Performance-Guided Surgery capabilities to European hospitals |
| | FDA 510(k) clearance: **Expanded General Surgery Indication** | • Expanded on-label applicability<br>• Can be utilized in 2.7 million annual procedures<br>• Key to future growth |
| **2Q'21** | FDA 510(k) submission: **Articulating Instruments** | • Widens the clinical utility to a broader number of surgeons<br>• Following approval, will initiate limited launch before full commercialization |
| | Upcoming FDA 510(k) submission: **Next Wave ISU Features** | • Next phase in progress towards Performance-Guided Surgery<br>• Will provide advanced Machine Vision and Augmented Intelligence capabilities<br>• Only robotic platform to offer scene recognition and surgical image analytics |

ASENSUS SURGICAL

# 5 Continue The Technological Advancement Of Senhance

## Focused Investment To Deliver The Future Of Surgery

### Senhance



Robust Digital Laparoscopy platform built on the fundamentals of MIS

### Intelligent Surgical Unit™ (ISU™)


Digital Platform capable of machine vision and augmented intelligence to enable real-time surgical analytics

### Performance-Guided Surgery

Clinical Intelligence to unlock superior outcomes with surgery

ASENSUS SURGICAL

# ISU: The First Machine Vision System In Robotic Surgery

Laying The Foundation For Digitizing  Surgery → Enable Performance-Guided Surgery




Vision Based Real-Time 3D Point to Point Measurement



Real-Time Defect Identification and Sizing

ASENSUS SURGICAL

# Performance-Guided Surgery




Improved Decision Making

Improved Collaboration

Improved Predictability

ASENSUS SURGICAL

# The Surgical Assurance Framework

## Unlocking Clinical Intelligence

### Intra-Op:
### **Perceptive Real-Time Guidance**

- Real-Time, Intra-Op Data
- Robotic Intervention
- Reduced Cognitive Load

### Pre-Op:
### **Intelligent Preparation**

- Setup Assistance
- OR Workflow
- Administrative Dashboard

**Performance-Guided Surgery**

### Post-Op:
### **Performance Analytics**

- Actionable Assessments
- Digital Replay
- Trend Analysis and Benchmarking

ASENSUS SURGICAL

# Senhance Connect

## Mobile In-OR Surgeon Communication System



Senhance® Connect

- Connects expert Senhance Surgeons across the Globe
- Streams multiple camera views and the endoscopic view simultaneously
- Allows 2-way screen sharing and annotation

ASENSUS SURGICAL

# Key Operational Accomplishments

# 2021 YTD Financial and Operational Highlights

Continued Momentum Building In 2021

## Operational Highlights

- **Two new lease agreements** signed year-to-date
- **Received CE Mark approval for**, and completed 100+ surgical procedures using, **the ISU**
- **Established EU training center** at Amsterdam Skills Centre in the Netherlands
- **Received FDA clearance for General Surgery** indication expansion
- **Submitted FDA 510(k) filing for articulating instruments**
- **Published results of first milestone study comparing health economic outcomes** versus Da Vinci as well as traditional laparoscopy

## Financial Highlights

- Q1-2021 Revenue: $2.1 million
  - Completed first buyout of a previously leased Senhance System
- Balance Sheet Highlights *(as of 3.31.2021)*
  - Cash & Restricted Cash ~ $166.4 million
  - Debt – None
  - Cash Runway – into 2024

ASENSUS SURGICAL

# Upcoming Milestones Support Operational Growth

## Clinical Adoption, Regulatory Success And Peer Reviewed Publications

- Regulatory Milestones (1H 2021)
  - File FDA 510(k) for next wave ISU Features
- Peer Reviewed Publications (2H 2021)
  - Health economic evidence in General Surgery and Gynecology
- Continued momentum and penetration of ISU and usage of Augmented Intelligence and Machine Vision technology in the US, EU and Asia
- Acceleration of new system installations and procedures volumes

ASENSUS SURGICAL

# Surgery Reimagined

Performance-Guided Surgery – next level technology that completely changes the idea of what's possible.